Science News

COLUMBIA, Md.--(BUSINESS WIRE)--COPT Defense Properties (NYSE: CDP) (“COPT Defense” or the “Company”) executed a build-to-suit lease in December 2025 with the University of Maryland’s (UMD) Applied Research Laboratory for Intelligence and Security (ARLIS) at 4400 River Road in College Park, Maryland, located in the UMD Discovery District. The Company is expected to commence construction of the 110,000 square foot, four-story Class A office development in the first quarter of 2026 and is schedul...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Januar...

VANCOUVER, British Columbia--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. will attend the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California....

WASHINGTON--(BUSINESS WIRE)--Cyclotrons have fundamentally transformed nuclear medicine and cancer therapy over the past decade, with major milestones driven by Best ABT, Best Cyclotron Systems (BCS) and TeamBest Global (TBG), under the leadership of Krishnan Suthanthiran. Their innovations have enabled more advanced diagnostic imaging, targeted therapies, and global expansion of life-saving technologies. BCS set out to design and build high-performance cyclotrons, establishing expertise in cyc...

LYON, France--(BUSINESS WIRE)--Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during do...

BELLINGHAM, Wash.--(BUSINESS WIRE)--SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company’s common stock and 1,000,000 pre-funded warrants....

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--United BioSource LLC (UBC) today announced it has acquired Evidinno Outcomes Research Inc. (Evidinno), a healthcare research consulting firm headquartered in Vancouver, Canada specializing in real-world evidence (RWE), epidemiology, evidence synthesis, and advanced statistical & economic analysis. UBC partners with biopharma to modernize evidence development and patient access pathways, ensuring therapies are safe, effective, and available to those who...

ORANGE, Conn.--(BUSINESS WIRE)--The Avangrid Foundation, the philanthropic arm of leading energy company Avangrid Inc., a member of the Iberdrola Group, today announced that it has awarded the Gulf of Maine Research Institute (GMRI) a $50,000 grant in support of their educational initiative, LabVenture: Building STEM skills for Maine. The grant will help the GMRI deliver immersive, hands-on science learning for approximately 8,300 middle school students across Maine. “The future of the energy i...

BOSTON--(BUSINESS WIRE)--1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced the publication of PEGASUS™, a multimodal AI model that achieves state-of-the-art accuracy in predicting and designing cell-permeable macrocyclic peptides. As featured in the Journal of Medicinal Chemistry, PEGASUS™ generated the first reported macrocyclic peptides containing more than two polar or charged fragments that demonstrate in vitro cell permeability, ad...